{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(6)"],"submitter":["Fan X"],"pubmed_abstract":["<h4>Background</h4>The study aimed to identify the relations of the absolute lymphocyte count (ALC) nadir during prophylactic cranial irradiation (PCI) and patient outcomes in limited-stage small cell lung cancer (LS-SCLC).<h4>Methods</h4>We analyzed 268 L S-SCLC patients who underwent PCI from 2012 to 2019. ALC values were collected prior, during, and 3 months post PCI. Kaplan-Meier and Cox regression analyses were performed to assess the relation of ALC to patient prognosis. Two nomograms were developed on the basis of clinical variables for survival prediction.<h4>Results</h4>Compared with the ALC before PCI (1.13 × 10<sup>9</sup> cells/L), the ALC nadir during PCI was significantly reduced by 0.68 × 10<sup>9</sup> cells/L (P < 0.001) and raised to 1.02 × 10<sup>9</sup> cells/L 3 months post PCI. Patients with a low ALC nadir during PCI (<0.68 × 10<sup>9</sup> cells/L) had inferior progression free survival (PFS) (median PFS: 17.2 <i>m</i> vs. 43.7 <i>m</i>, P = 0.019) and overall survival (OS) (median OS: 29.0 <i>m</i> vs 39.1 <i>m</i>, P = 0.012). Multivariate Cox analysis revealed that age, smoking history, clinical stage, and ALC nadir were independent OS (P = 0.006, P = 0.005, P < 0.001 and P = 0.027, respectively), as well as independent PFS predictors (P = 0.032, P = 0.012, P = 0.012 and P = 0.018, respectively). After internal cross-validation, the corrected concordance indices of the predictive nomograms for PFS and OS were 0.637 and 0.663, respectively.<h4>Conclusion</h4>LS-SCLC patients with a low ALC nadir during PCI likely have worse survival outcomes. Dynamic evaluation of the ALC during PCI is recommended for LS-SCLC patients."],"journal":["Heliyon"],"pagination":["e16483"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10220366"],"repository":["biostudies-literature"],"pubmed_title":["Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer."],"pmcid":["PMC10220366"],"pubmed_authors":["Fan X","Yang L","Wang S","Zou B","Qin W","Fan B","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Prophylactic cranial irradiation-related lymphopenia affects survival in patients with limited-stage small cell lung cancer.","description":"<h4>Background</h4>The study aimed to identify the relations of the absolute lymphocyte count (ALC) nadir during prophylactic cranial irradiation (PCI) and patient outcomes in limited-stage small cell lung cancer (LS-SCLC).<h4>Methods</h4>We analyzed 268 L S-SCLC patients who underwent PCI from 2012 to 2019. ALC values were collected prior, during, and 3 months post PCI. Kaplan-Meier and Cox regression analyses were performed to assess the relation of ALC to patient prognosis. Two nomograms were developed on the basis of clinical variables for survival prediction.<h4>Results</h4>Compared with the ALC before PCI (1.13 × 10<sup>9</sup> cells/L), the ALC nadir during PCI was significantly reduced by 0.68 × 10<sup>9</sup> cells/L (P < 0.001) and raised to 1.02 × 10<sup>9</sup> cells/L 3 months post PCI. Patients with a low ALC nadir during PCI (<0.68 × 10<sup>9</sup> cells/L) had inferior progression free survival (PFS) (median PFS: 17.2 <i>m</i> vs. 43.7 <i>m</i>, P = 0.019) and overall survival (OS) (median OS: 29.0 <i>m</i> vs 39.1 <i>m</i>, P = 0.012). Multivariate Cox analysis revealed that age, smoking history, clinical stage, and ALC nadir were independent OS (P = 0.006, P = 0.005, P < 0.001 and P = 0.027, respectively), as well as independent PFS predictors (P = 0.032, P = 0.012, P = 0.012 and P = 0.018, respectively). After internal cross-validation, the corrected concordance indices of the predictive nomograms for PFS and OS were 0.637 and 0.663, respectively.<h4>Conclusion</h4>LS-SCLC patients with a low ALC nadir during PCI likely have worse survival outcomes. Dynamic evaluation of the ALC during PCI is recommended for LS-SCLC patients.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-22T21:58:09.977Z","creation":"2025-04-06T03:55:21.019Z"},"accession":"S-EPMC10220366","cross_references":{"pubmed":["37251477"],"doi":["10.1016/j.heliyon.2023.e16483"]}}